BNTC Gene Therapy Penny Stock

NASDAQ:BNTC   Benitec Biopharma Inc
BTC Benitec Biopharma is sitting now at a key support from which we can expect a bounce.

We know that earlier this year they had a 7.5mil offering price to the public of $4.25 per share and that Morgan Stanley has a 5.2% stake in the genetic drug company.

Benitec's "proprietary platform, called DNA-directed RNA interference, or ddRNAi, combines RNA interference, or RNAi, with gene therapy to create medicines that facilitate sustained silencing of disease-causing genes following a single administration.

Market Cap 22.472Mil

My price targets are 4.70 and 5.70 usd.


The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.